News

April 17, 2017

Innovative Microbiome-based IBD Therapeutics to Be Developed Under New Partnership

News

Takeda Pharmaceutical, a Japanese biopharmaceutical company, announced a strategic new collaboration with NuBiyota to develop Microbial Ecosystem Therapeutics, a new form of treatment for patients with gastroenterology disorders who fail to respond ... Read more

April 13, 2017

Vitality Biopharma Appoints Regulatory Advisor for Cannabis-Derived Prodrugs Program

News

Vitality Biopharma has appointed Tracy Rockney, co-founder and chief operating officer at OneSource Regulatory, to the position of senior regulatory advisor. She will be responsible for the regulatory development of ... Read more

April 12, 2017

Two National Groups Partner to Develop Shared IBD Decision-making Program

News

The Crohn’s & Colitis Foundation and the American Gastroenterological Association (AGA) are collaborating with Pfizer to develop a program that aims to jumpstart advances in the area of shared decision-making ... Read more

April 11, 2017April 11, 2017

Yoga Improves Quality of Life for Ulcerative Colitis Patients, Clinical Trial Finds

News

Regular supervised 90-minute weekly yoga sessions over a 12-week period improved quality of life and reduced disease activity in people with ulcerative colitis (UC), compared to patients who got only self-care advice. ... Read more

April 10, 2017

Redhill to Promote EnteraGam, Aid for IBS Patients with Chronic Diarrhea, in US

News

EnteraGam, a medical food product for the management of diarrhea-predominant irritable bowel syndrome (IBS-D), is now fully licensed in the United States to Redhill Biopharma, under an exclusive license agreement ... Read more

April 7, 2017May 4, 2017

Perianal Fistulas in Crohn’s Patients Effectively Treated in Long Term with Cx601, Study Finds

News

TiGenix’s lead compound Cx601 is a safe and effective long-term treatment of complex perianal fistulas in Crohn’s disease patients, a clinical trial reports. The positive results come from the 104-week extension ... Read more

April 6, 2017April 6, 2017

Finch, Takeda to Jointly Develop Microbiome Therapeutic for Ulcerative Colitis

News

Japan’s Takeda Pharmaceutical and Boston-based Finch Therapeutics will jointly develop the drug FIN-524 to treat ulcerative colitis, a form of inflammatory bowel disease (IBD). FIN-524 is Finch’s first microbiotic product candidate. The company says its live biotherapeutic product ... Read more

April 5, 2017April 7, 2017

Bacteria That May Cause Crohn’s, and Its Link to Animals, Are Key Topics at Philadelphia Event

News

Growing evidence suggests that the Mycobacterium avium subspecies paratuberculosis (MAP) is the bacteria that causes Crohn’s disease and that the disease can be transmitted from animals to humans, scientists at ... Read more

April 4, 2017

Use of Antibiotics Early in Life May Lead to IBD in Adults, Mouse Study Suggests

News

The use of antibiotics very early in life may alter the normal development of the gut bacteria, which may play a role in the development of inflammatory bowel disease (IBD), ... Read more

April 3, 2017

FDA Reports of Crohn’s Disease Treatment Side Effects Have Increased, Analysis Finds

News

Drugs used to treat Crohn’s disease and other autoimmune disorders are among those with the greatest number of reported side effects filed with the U.S. Food and Drug Administration (FDA), ... Read more